Acquisition provides access to key longevity data designed to enable personalized, predictive and longitudinal health insights.
The AI-enabled personalized healthcare market is hotting up, with the likes of Function Health and Superpower both hitting the headlines recently. This week, another player emerged as AI-driven consumer health platform Hundred Health announced the acquisition of personalized health and wellness provider BellSant in an all-stock deal aimed at integrating a wealth of longevity research into its offering.
Hundred aims to help its users achieve their optimum level of health through a combination of comprehensive blood-based diagnostics, wearable data and AI-powered analysis. For a yearly subscription of $499, the platform interprets over 115 biomarkers and integrates insights from daily health behaviors, offering users a real-time understanding of their health trajectory. With both Function and Superpower charging the same membership fee, it appears that $499 per year is the going rate in this nascent sector.
Hundred is interested in BellSant’s scientific foundation, developed by researchers from institutions like Johns Hopkins, Harvard, Columbia and Stanford, which it says offers proprietary data and predictive models across areas including genomics, metabolic biology, sleep science and cognitive health. Through the acquisition, the company claims it will gains access to validated biomarker models, optimal health ranges and demographic personalization logic, which will be folded into its AI engine, enhancing its ability to deliver personalized, predictive and longitudinal health insights.
Rather than presenting users with raw data, Hundred claims its platform converts complex scientific findings into clear, actionable narratives that help its users understand and improve their health over time. The acquisition comes as the company wraps up its “closed beta” pilot and prepares for its full launch this summer, claiming to have more than 50,000 people on its waitlist.
As part of the acquisition, Hundred says that select “engineering and data talent” from BellSant will join the company, while BellSant founder Matt Fellowes joins its advisory board.
“Matt and the BellSant team have assembled one of the world’s richest longevity datasets,” said Hundred Health CEO Tyler Smith. “By folding their science directly into our platform, every member will have on-demand access to the collective expertise of dozens of leading researchers to inform smarter, personalized health decisions.”
“Choosing a future for BellSant’s platform wasn’t a decision we made lightly,” said Fellowes. “After careful evaluation, it was clear that Hundred represented not just the right home but the right future. Tyler and his team aren’t just building technology, they’re building a fundamentally better model of healthcare.”
